Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
...
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 424
- Registration Number
- NCT03236987
- Locations
- 🇫🇷
Saint Joseph Hospital, Marseille, France
🇫🇷CHU Amiens Picardie, Amiens, Picardie, France
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 672
- Registration Number
- NCT02581527
- Locations
- 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵GENETUP, National Anti-TB Association, Kathmandu, Nepal
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02477852
- Locations
- 🇨🇳
Beijing chest hospital, Beijing, Beijing, China
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 31
- Registration Number
- NCT02372383
- Locations
- 🇺🇸
Children's Hospital Colroado, Aurora, Colorado, United States
Assessing PA-824 for Tuberculosis (the APT Trial)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 157
- Registration Number
- NCT02256696
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 97
- Registration Number
- NCT02024555
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.